Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;42(12):1417-1420.
doi: 10.1002/cac2.12353. Epub 2022 Aug 22.

Evaluation of immune response to anti-COVID-19 booster in cancer patients and chronic medical cannabis users and its association with circulating Eosinophils levels

Cohen Idan  1 , Campisi-Pinto Salvatore  2 , Rozenberg Orit  3 , Abaev Ariel  3 , Khoury Marah  3 , Agbaria Dana  3 , Eitam Harel  3 , Colodner Raul  3 , Khoury Mona  1   4 , Shalabna Hassan  1 , Samih Yousef  1 , Mahamid Camel  1 , Abu-Amna Mahmoud  1   4 , Bar-Sela Gil  1   4
Affiliations

Evaluation of immune response to anti-COVID-19 booster in cancer patients and chronic medical cannabis users and its association with circulating Eosinophils levels

Cohen Idan et al. Cancer Commun (Lond). 2022 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

FIGURE 1
FIGURE 1
IgG titer levels and CBC parameters over various groups. (A) IgG titers (Au/mL) in relation to two factors of variance, cannabis use (user, non‐users) and cancer status (non‐cancer, cancer). On each box plot, the central mark indicates the median, and the bottom and top edges of the box indicate the 25th and 75th percentiles, respectively. Means are plotted individually using the ‘full dots’ marker symbol. (B) Incidence (%) of high responders (Ig > 4000) over time (days from vaccination to the measurement of anti‐COVID‐19 immunoglobulin G [IgG]). (C) Correlation of CBC levels and cell counts, in relation to two factors of variance, IgG response (high responders > 4000 AU/mL vs. low responders ≤4000 AU/mL) and time of measurement (Sampling before booster BNT162b2 booster dose vs. Sampling after booster after BNT162b2 booster dose). Each box represents a different tested blood component. The left side of each box shows measurements before the BNT162b2 booster dose (Sampling before booster), and the right side shows measurements after the BNT162b2 booster dose (Sampling after booster). Platelet (PLT), Hemoglobin (HB), White blood cells (WBC), Neutrophil (NEU), Monocytes (MONO), Eosinophils (EOS), Lymphocyte (LYM)
See this image and copyright information in PMC

References

    1. Barda N, Dagan N, Cohen C, Hernan MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID‐19 vaccine for preventing severe outcomes in Israel: An observational study. Lancet. 2021;398(10316):2093–100. - PMC - PubMed
    1. Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C, et al. Third BNT162b2 vaccination neutralization of SARS‐CoV‐2 omicron infection. N Engl J Med. 2022;386(5):492–4. - PMC - PubMed
    1. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS‐CoV‐2: A multicenter study during the COVID‐19 outbreak. Cancer Discov. 2020;10(6):783–91. - PMC - PubMed
    1. Fendler A, de Vries EGE, GeurtsvanKessel CH, Haanen JB, Wormann B, Turajlic S, et al. COVID‐19 vaccines in patients with cancer: Immunogenicity, efficacy and safety. Nat Rev Clin Oncol. 2022;19(6):385–401. - PMC - PubMed
    1. Goshen‐Lago T, Waldhorn I, Holland R, Szwarcwort‐Cohen M, Reiner‐Benaim A, Shachor‐Meyouhas Y, et al. Serologic Status and Toxic Effects of the SARS‐CoV‐2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol. 2021;7(10):1507–13. - PMC - PubMed

Publication types

Substances